Paul Hartmann
Market Cap
€1.0b
Last Updated
2020/01/23 20:54 UTC
Data Sources
Company Financials
Executive Summary
Paul Hartmann AG manufactures and sells medical and hygiene products for wound care, incontinence, disinfection, and surgical efficiency in Europe, North and South America, Africa, Asia, and Oceania.
Rewards
Risk Analysis
No risks detected for PHH2 from our risk checks.
Snowflake Analysis
Flawless balance sheet average dividend payer.
Similar Companies
Share Price & News
How has Paul Hartmann's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: PHH2 has not had significant price volatility in the past 3 months.
Market Performance
7 Day Return
0.7%
PHH2
2.2%
DE Medical Equipment
-0.3%
DE Market
1 Year Return
-4.6%
PHH2
36.1%
DE Medical Equipment
14.0%
DE Market
Return vs Industry: PHH2 underperformed the German Medical Equipment industry which returned 35.7% over the past year.
Return vs Market: PHH2 underperformed the German Market which returned 17.1% over the past year.
Shareholder returns
| PHH2 | Industry | Market | |
|---|---|---|---|
| 7 Day | 0.7% | 2.2% | -0.3% |
| 30 Day | 0.7% | 4.7% | 0.5% |
| 90 Day | -4.0% | 18.0% | 4.5% |
| 1 Year | -2.4%-4.6% | 38.2%36.1% | 17.6%14.0% |
| 3 Year | -28.0%-32.1% | 146.2%139.8% | 14.3%4.2% |
| 5 Year | -6.7%-14.8% | 296.7%276.7% | 26.0%8.9% |
Price Volatility Vs. Market
How volatile is Paul Hartmann's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 weeks ago | Simply Wall St
Should Paul Hartmann AG (FRA:PHH2) Focus On Improving This Fundamental Metric?1 month ago | Simply Wall St
With A -13% Earnings Drop, Did Paul Hartmann AG (FRA:PHH2) Really Underperform?2 months ago | Simply Wall St
Is Paul Hartmann (FRA:PHH2) A Risky Investment?Valuation
Is Paul Hartmann undervalued compared to its fair value and its price relative to the market?
13.88x
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: PHH2 (€288) is trading above our estimate of fair value (€198.32)
Significantly Below Fair Value: PHH2 is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: PHH2 is good value based on its PE Ratio (13.9x) compared to the Medical Equipment industry average (44.9x).
PE vs Market: PHH2 is good value based on its PE Ratio (13.9x) compared to the German market (20.6x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate PHH2's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: PHH2 is good value based on its PB Ratio (1.2x) compared to the DE Medical Equipment industry average (5.8x).
Next Steps
Future Growth
How is Paul Hartmann forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
12.5%
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Paul Hartmann has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Next Steps
- Examine whether Paul Hartmann is trading at an attractive price based on how much it is expected to earn in the future, and relative to its industry peers and the wider market.
- Paul Hartmann competitive advantages and company strategy can generally be found in its financial reports archived here.
- Explore growth companies in the Healthcare industry.
Past Performance
How has Paul Hartmann performed over the past 5 years?
2.7%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: PHH2 has high quality earnings.
Growing Profit Margin: PHH2's current net profit margins (3.4%) are lower than last year (4%).
Past Earnings Growth Analysis
Earnings Trend: PHH2's earnings have grown by 2.7% per year over the past 5 years.
Accelerating Growth: PHH2's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: PHH2 had negative earnings growth (-12.8%) over the past year, making it difficult to compare to the Medical Equipment industry average (23.9%).
Return on Equity
High ROE: PHH2's Return on Equity (8.7%) is considered low.
Return on Assets
Return on Capital Employed
Next Steps
Financial Health
How is Paul Hartmann's financial position?
Financial Position Analysis
Short Term Liabilities: PHH2's short term assets (€867.6M) exceed its short term liabilities (€400.7M).
Long Term Liabilities: PHH2's short term assets (€867.6M) exceed its long term liabilities (€301.6M).
Debt to Equity History and Analysis
Debt Level: PHH2's debt to equity ratio (11.9%) is considered satisfactory.
Reducing Debt: PHH2's debt to equity ratio has reduced from 21.6% to 11.9% over the past 5 years.
Debt Coverage: PHH2's debt is well covered by operating cash flow (130.2%).
Interest Coverage: PHH2's interest payments on its debt are well covered by EBIT (68x coverage).
Balance Sheet
Inventory Level: PHH2 has a high level of physical assets or inventory.
Debt Coverage by Assets: PHH2's debt is covered by short term assets (assets are 8.1x debt).
Next Steps
Dividend
What is Paul Hartmann's current dividend yield, its reliability and sustainability?
2.43%
Current Dividend Yield
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: PHH2's dividend (2.43%) is higher than the bottom 25% of dividend payers in the German market (1.38%).
High Dividend: PHH2's dividend (2.43%) is low compared to the top 25% of dividend payers in the German market (3.53%).
Stability and Growth of Payments
Stable Dividend: PHH2's dividends per share have been stable in the past 10 years.
Growing Dividend: PHH2's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its reasonably low payout ratio (33.7%), PHH2's dividend payments are well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.
Next Steps
Management
What is the CEO of Paul Hartmann's salary, the management and board of directors tenure and is there insider trading?
7.7yrs
Average management tenure
CEO
Britta Fuenfstueck 0
1yrs
Tenure
Ms. Britta Fuenfstueck has been Chief Executive Officer at Paul Hartmann AG since January 1, 2019 and its Management Board since January 1, 2019. Ms. Fuenfstueck served as Chairman of the Management Board ...
Management Age and Tenure
7.7yrs
Average Tenure
Experienced Management: PHH2's management team is seasoned and experienced (7.7 years average tenure).
Board Age and Tenure
11.8yrs
Average Tenure
Experienced Board: PHH2's board of directors are seasoned and experienced ( 11.8 years average tenure).
Insider Trading
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Management Team
Raymund Heinen
Chief Process Officer & Member of the Management Board
- Tenure: 4.3yrs
Michel Kuehn (65yo)
Chief Hygiene Officer & Member of Management Board
- Tenure: 11.3yrs
Michael Banz
Vice President of Corporate Legal
Ralf Fenske
Senior Vice President of Corporate Accounting
Peter Halbauer
Head of Group Purchasing Management
- Tenure: 12yrs
Gabriele Müller
Vice President of Human Resources Management
- Tenure: 9yrs
Michael Brauner
Executive Managing Director of SANIMED Group Germany
- Tenure: 6.3yrs
Christian Sievert
Senior Vice President Business Unit Risk Prevention
Britta Fuenfstueck
CEO & Member of Management Board
- Tenure: 1yrs
François Georgelin
Member of the Management Board
Board Members
Joachim Schielke (70yo)
Member of Supervisory Board
- Tenure: 11.8yrs
- Compensation: €22.50k
Fritz-Jürgen Heckmann
Chairman of Supervisory Board
- Tenure: 14.5yrs
- Compensation: €69.50k
Werner Casper
Member of Supervisory Board
- Compensation: €22.50k
Eduard Schleicher
Member of Supervisory Board
- Tenure: 11.8yrs
- Compensation: €53.83k
Gerhard Hirth
Member of Supervisory Board
- Tenure: 11.8yrs
- Compensation: €22.50k
Rinaldo Riguzzi (73yo)
Member of Supervisory Board
- Tenure: 6.5yrs
Christine Geppert
Member of Supervisory Board
- Compensation: €22.50k
Wolfgang Röhrl
Vice President Operations Management Medical Production & Member of Supervisory Board
- Tenure: 2yrs
Ralf Willeck
Deputy Chairman of the Supervisory Board
Yvonne Brix
Member of Supervisory Board
- Tenure: 6.7yrs
Company Information
Paul Hartmann AG's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Paul Hartmann AG
- Ticker: PHH2
- Exchange: DB
- Founded: 1818
- Industry: Health Care Supplies
- Sector: Healthcare
- Market Cap: €1.002b
- Shares outstanding: 3.55m
- Website: https://hartmann.info
Number of Employees
Location
- Paul Hartmann AG
- Paul-Hartmann-Strasse 12
- Heidenheim
- Baden-Württemberg
- 89522
- Germany
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| PHH2 | DB (Deutsche Boerse AG) | Yes | Common Shares | DE | EUR | Jan 1992 |
| PLHN.F | OTCPK (Pink Sheets LLC) | Yes | Common Shares | US | USD | Jan 1992 |
Biography
Paul Hartmann AG manufactures and sells medical and hygiene products for wound care, incontinence, disinfection, and surgical efficiency in Europe, North and South America, Africa, Asia, and Oceania. The company offers disinfectant products for hands, surface, and instruments; cleaning, skin care, and skin antisepsis products, as well as Sterillium, a hand disinfectant; incontinence management products; and personal healthcare products, such as diagnostic devices and first aid products. It also provides single-use and pre-surgical products, disposable surgical gloves, clothing and gowns, and disposable drapes for use in operating theatres, treatment rooms, and wards; and wound management solutions, including traditional compresses, bandages, hydro therapy products. The company offers its products and services to nursing and healthcare professionals, home residents, and patients. Paul Hartmann AG was founded in 1818 and is based in Heidenheim, Germany.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/01/23 20:54 |
| End of Day Share Price | 2020/01/23 00:00 |
| Earnings | 2019/06/30 |
| Annual Earnings | 2018/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.